Basel, May 16, 2019 - Novartis will present data from across its oncology portfolio at the upcoming 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 31-June 4 in Chicago; and the 24th Annual Congress of the European Hematology Association (EHA), scheduled for June 13-16 in Amsterdam. The more than 100 abstracts to be presented underscore Novartis' relentless commitment to addressing unmet needs in cancer and hematology through innovation and research. Data will focus on a range of disease areas, including breast cancer, lung cancer, melanoma and sickle cell disease, as well as leukemias, other hematologic disorders and solid tumors.

"We are excited to share the latest information about our transformative therapies in cancer and serious blood disorders at ASCO and EHA this year," said Susanne Schaffert, CEO, Novartis Oncology. "New data will showcase our scientific and patient-focused prowess across a range of the most difficult-to-treat diseases in the world."

Novartis data at the 2019 ASCO Annual Congress will highlight the following:

Kisqali overall survival results, and additional data on treatment sequencing and patient reported outcomes in HR+/HER2- advanced breast cancer:

Long-term and new analyses of the Tafinlar+Mekinist COMBI trials in melanoma:

Results from GEOMETRY study investigating capmatinib (INC280) in NSCLC:

Analyses on treatment of advanced solid tumors and hematologic malignancies with spartalizumab (PDR001) in combination with other agents:

A study evaluating Kymriah® (tisagenlecleucel)*** in follicular lymphoma:

Long-term treatment-free remission (TFR) data, after Tasigna treatment discontinuation, in patients with CML:

Additional data presented at ASCO include:

Advanced Accelerator Applications, a Novartis company and leader in nuclear medicine theragnostics, will present additional analyses from the NETTER-1 study evaluating Lutathera® (lutetium Lu 177 dotatate)**** in patients with progressive midgut neuroendocrine tumors:

Sandoz, a Novartis division, the pioneer and global leader in biosimilars, will present data for the company's biosimilar pegfilgrastim:

Additional data from Sandoz to be featured online by ASCO include:

Novartis data at the 2019 EHA Annual Congress will highlight the following:

Retrospective data for investigational compound crizanlizumab (SEG101): 

Expert consensus paper on tapering and discontinuation of TPO-RAs and additional results of worldwide ITP impact survey:

Data on the investigational compound asciminib (ABL001) in combination with other tyrosine kinase inhibitors in previously treated CML patients:

Data analyses with a 3.7-year follow-up for Tasigna TFR in CML:

Abstracts analyzing the safety and efficacy of Kymriah in acute lymphoblastic leukemia, and on regrading of adverse events in diffuse large B-cell lymphoma:

Safety and efficacy of Jakavi® (ruxolitinib)***** in myelofibrosis (MF) and anemia, and additional results from a large-scale survey on the impact of myeloproliferative neoplasms:

New and updated data evaluating the efficacy and safety of Rydapt® (midostaurin) in patients with acute myeloid leukemia (AML) and different genetic mutational status:

Throughout the 2019 ASCO Annual Meeting and EHA Annual Meeting, Novartis will host dedicated content on Twitter, Facebook, and LinkedIn, featuring leader and patient insights and perspectives on the emerging trends in cancer care and research.

Product Information 
Approved indications for products vary by country and not all indications are available in every country. The product safety and efficacy profiles have not yet been established outside the approved indications. Because of the uncertainty of clinical trials, there is no guarantee that compounds will become commercially available with additional indications.

For full prescribing information, including approved indications and important safety information about marketed products, please visit 
https://www.novartisoncology.com/news/product-portfolio.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

* Kisqali was developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals.
** Capmatinib (INC280) is an investigational, oral and selective MET inhibitor licensed to Novartis by Incyte Corporation in 2009. Under the Agreement, Incyte granted Novartis worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications.
*** Novartis and the University of Pennsylvania's Perelman School of Medicine (Penn) have a global collaboration to research, develop and commercialize chimeric antigen receptor T cell (CAR-T) therapies, including Kymriah, for the investigational treatment of cancers.
**** Lutathera is a registered trademark of Advanced Accelerator Applications, a Novartis company.  
***** Jakavi is a registered trademark of Novartis AG in countries outside the United States. Jakafi is a registered trademark of Incyte Corporation. Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization outside the United States.

# # #

Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com

Antonio Ligi
Novartis Global Media Relations
+41 61 324 1374 (direct)
+41 79 723 3681 (mobile)
antonio.ligi@novartis.com 		Julie Masow
Novartis Oncology Media Relations
+1 862 778 7220 (direct)
+1 862 579 8456 (mobile)
julie.masow@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central   North America  
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425    
Isabella Zinck +41 61 324 7188    


Novartis Pharma AG       Novartis Pharmaceuticals Corporation
CH-4002 Basel Switzerland © 2019 Novartis 5/19 G-ONC-1211773  East Hanover, New Jersey 07936-1080

Attachment